NASDAQ Biotechnology Index semi-annual re-ranking to become effective May 24, 2010

The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index^® (Nasdaq:NBI), which will become effective prior to market open on Monday, May 24, 2010.

The following nine securities will be added to the Index: Affymax, Inc. (Nasdaq:AFFY), China Biologic Products, Inc. (Nasdaq:CBPO), Curis, Inc. (Nasdaq:CRIS), Cytori Therapeutics, Inc. (Nasdaq:CYTX), Eurand N.V. (Nasdaq:EURX), Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ), MAP Pharmaceuticals, Inc. (Nasdaq:MAPP), Sinovac Biotech Ltd. (Nasdaq:SVA), and Talecris Biotherapeutics Holdings Corp. (Nasdaq:TLCR).

The Index is designed to track the performance of a set of NASDAQ listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. For more information about the NASDAQ Biotechnology Index, including detailed eligibility criteria, visit https://indexes.nasdaqomx.com/.

As a result of the re-ranking, the following four securities will be removed from the Index: Adolor Corporation (Nasdaq:ADLR), Columbia Laboratories, Inc. (Nasdaq:CBRX), Discovery Laboratories, Inc. (Nasdaq:DSCO), and Poniard Pharmaceuticals, Inc. (Nasdaq:PARD).

The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index(SM) Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the NASDAQ Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on various exchanges.

Source NASDAQ OMX Group